Unity Biotechnology Inc (NAS:UBX)
$ 0.999 -0.036 (-3.48%) Market Cap: 16.83 Mil Enterprise Value: 9.10 Mil PE Ratio: 0 PB Ratio: 1.19 GF Score: 32/100

UNITY Biotechnology Inc To Discuss Phase 2 BEHOLD Program Update Call Transcript

Nov 01, 2022 / 12:00PM GMT
Release Date Price: $2.75 (-3.85%)
Tara Sobierajski;LifeSci Events;Senior Manager
Client Success,

Good morning, and welcome to the UNITY Biotechnology Investor Call on the Phase II Clinical Update in the BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema. (Operator Instructions) As a reminder, this call is being recorded, and a replay will be made available on the UNITY website following the conclusion of the event.

I'd now like to turn the call over to Lynne Sullivan, Chief Financial Officer of UNITY Biotechnology. Please go ahead, Lynne.

Lynne Marie Sullivan
Unity Biotechnology, Inc. - CFO & Head of Corporate Development

Thanks, Tara. Good morning, and thank you for joining UNITY Biotechnology's conference call to review 24-week data from the Phase II BEHOLD study of UBX1325 in patients with DME.

With me on today's call is Anirvan Ghosh, the CEO of UNITY Biotechnology; Jamie Dananberg, our Chief Medical Officer; and myself, Lynne Sullivan, the Chief Financial Officer. We're fortunate to have Dr. Arshad Khanani, Director

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot